Understanding how cancer metabolism affects chemotherapy resistance in pancreatic cancer
Cancer and stromal metabolic reprogramming drives chemotherapy resistance in human models of pancreatic cancer
This study is looking into why pancreatic cancer doesn't respond well to regular chemotherapy and hopes to find new ways to make these treatments work better for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11073933 on NIH RePORTER |
What this research studies
This research investigates the reasons behind the poor response of pancreatic cancer to standard chemotherapy treatments. It focuses on how changes in the metabolism and signaling of both cancer cells and surrounding supportive cells (stroma) contribute to the development of resistance to these therapies. By studying these interactions, the research aims to identify new therapeutic strategies that could enhance the effectiveness of existing treatments. Patients may benefit from insights that lead to improved treatment options tailored to their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer who are undergoing or have undergone chemotherapy.
Not a fit: Patients with pancreatic cancer who are not receiving chemotherapy or those with very early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving patient outcomes and survival rates.
How similar studies have performed: Previous research has shown promise in understanding metabolic changes in cancer cells and their role in treatment resistance, suggesting that this approach could yield significant insights.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Singh, Pankaj Kumar — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Singh, Pankaj Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.